JP2009522281A - 翻訳機能障害に基づく治療法 - Google Patents

翻訳機能障害に基づく治療法 Download PDF

Info

Publication number
JP2009522281A
JP2009522281A JP2008548731A JP2008548731A JP2009522281A JP 2009522281 A JP2009522281 A JP 2009522281A JP 2008548731 A JP2008548731 A JP 2008548731A JP 2008548731 A JP2008548731 A JP 2008548731A JP 2009522281 A JP2009522281 A JP 2009522281A
Authority
JP
Japan
Prior art keywords
cell
cancer
compound
eif4e
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008548731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522281A5 (https=
Inventor
ボーデン，キャサリン，エル．ビー．
ジェーミソン，ゴードン，エー．
カルコビッチ，ビルヤナ
ケントシス，アレックス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translational Therapeutics Inc
Original Assignee
Translational Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Therapeutics Inc filed Critical Translational Therapeutics Inc
Publication of JP2009522281A publication Critical patent/JP2009522281A/ja
Publication of JP2009522281A5 publication Critical patent/JP2009522281A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2008548731A 2005-12-28 2006-12-28 翻訳機能障害に基づく治療法 Pending JP2009522281A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75446105P 2005-12-28 2005-12-28
US79404806P 2006-04-22 2006-04-22
US84858306P 2006-09-29 2006-09-29
US85440406P 2006-10-25 2006-10-25
PCT/US2006/049450 WO2007123579A2 (en) 2005-12-28 2006-12-28 Translational dysfunction based therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015182943A Division JP2016040263A (ja) 2005-12-28 2015-09-16 翻訳機能障害に基づく治療法

Publications (2)

Publication Number Publication Date
JP2009522281A true JP2009522281A (ja) 2009-06-11
JP2009522281A5 JP2009522281A5 (https=) 2013-04-11

Family

ID=38625451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008548731A Pending JP2009522281A (ja) 2005-12-28 2006-12-28 翻訳機能障害に基づく治療法
JP2015182943A Pending JP2016040263A (ja) 2005-12-28 2015-09-16 翻訳機能障害に基づく治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015182943A Pending JP2016040263A (ja) 2005-12-28 2015-09-16 翻訳機能障害に基づく治療法

Country Status (6)

Country Link
EP (1) EP1971690B1 (https=)
JP (2) JP2009522281A (https=)
AU (1) AU2006342447B2 (https=)
CA (1) CA2633715C (https=)
NZ (1) NZ569883A (https=)
WO (1) WO2007123579A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5602349B2 (ja) * 2007-11-20 2014-10-08 旭化成ファーマ株式会社 ミゾリビン及び／又はリバビリンの測定方法
WO2009118712A2 (en) * 2008-03-27 2009-10-01 Ecole Polytechnique Federale De Lausanne (Epfl) Novel dihydroxypyrrolidine derivatives as anti-cancer agents
US8599383B2 (en) 2009-05-06 2013-12-03 The Regents Of The University Of California Optical cytometry
CA2843445C (en) 2011-08-02 2019-09-24 The Regents Of The University Of California Rapid, massively parallel single-cell drug response measurements via live cell interferometry
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
JP6367318B2 (ja) 2013-05-24 2018-08-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 質量応答における変化による望ましいｔリンパ球の同定
WO2020214806A1 (en) * 2019-04-16 2020-10-22 The Regents Of The University Of California Protein translational control

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1010380A (en) * 1963-08-07 1965-11-17 Shionogi & Co Antibiotic showdomycin and a process for its production
JPH03503049A (ja) * 1988-01-07 1991-07-11 ユニバーシティ・オブ・リバプール 腺癌を治療するための逆転写酵素阻害剤
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
JP2004509061A (ja) * 2000-02-15 2004-03-25 リバファーム・インコーポレイテッド カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ
WO2004100995A1 (en) * 2003-05-15 2004-11-25 Hemosol Lp Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
US20050159372A1 (en) * 2000-02-15 2005-07-21 Robert Tam Nucleoside analogs with carboxamidine modified monocyclic base
JP2005524662A (ja) * 2002-02-28 2005-08-18 ビオタ インコーポレーティッド ヌクレオシド５’−一リン酸模倣物およびこれらのプロドラッグ

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
FI63596C (fi) 1981-10-16 1983-07-11 Orion Yhtymae Oy Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
FI71768C (fi) 1984-02-17 1987-02-09 Orion Yhtymae Oy Foerbaettrade nykleinsyrareagenser och foerfarande foer deras framstaellning.
GB8432118D0 (en) 1984-12-19 1985-01-30 Malcolm A D B Sandwich hybridisation technique
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4751177A (en) 1985-06-13 1988-06-14 Amgen Methods and kits for performing nucleic acid hybridization assays
WO1990001564A1 (en) 1988-08-09 1990-02-22 Microprobe Corporation Methods for multiple target analyses through nucleic acid hybridization
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304620D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Compounds
EP0728202A4 (en) 1993-11-12 1997-04-23 Univ Case Western Reserve EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
GB9525639D0 (en) 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
EP0980280B1 (en) 1997-10-01 2005-02-09 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
US6230802B1 (en) 1998-07-24 2001-05-15 Schlumberger Technology Corporation Method and apparatus for gravel packing a well
US6135976A (en) 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1010380A (en) * 1963-08-07 1965-11-17 Shionogi & Co Antibiotic showdomycin and a process for its production
JPH03503049A (ja) * 1988-01-07 1991-07-11 ユニバーシティ・オブ・リバプール 腺癌を治療するための逆転写酵素阻害剤
JP2004509061A (ja) * 2000-02-15 2004-03-25 リバファーム・インコーポレイテッド カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ
US20050159372A1 (en) * 2000-02-15 2005-07-21 Robert Tam Nucleoside analogs with carboxamidine modified monocyclic base
JP2005524662A (ja) * 2002-02-28 2005-08-18 ビオタ インコーポレーティッド ヌクレオシド５’−一リン酸模倣物およびこれらのプロドラッグ
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
WO2004100995A1 (en) * 2003-05-15 2004-11-25 Hemosol Lp Targeted delivery of anti-viral compounds through hemoglobin bioconjugation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 47, no. 6, JPN6012041221, 2003, pages 1912 - 1921, ISSN: 0002299023 *
CANCER RESEARCH, vol. 33, JPN6012041219, 1973, pages 2619 - 2623, ISSN: 0002299020 *
PNAS, vol. 101, no. 52, JPN6012041218, 2004, pages 18105 - 18110, ISSN: 0002299021 *
RNA, vol. 11, no. 10, JPN6012041216, 2005, pages 1505 - 1513, ISSN: 0002299022 *

Also Published As

Publication number Publication date
EP1971690A4 (en) 2009-11-11
CA2633715A1 (en) 2007-11-01
WO2007123579A3 (en) 2008-02-28
WO2007123579B1 (en) 2008-04-24
EP1971690B1 (en) 2018-10-17
WO2007123579A2 (en) 2007-11-01
CA2633715C (en) 2016-06-14
AU2006342447A1 (en) 2007-11-01
EP1971690A2 (en) 2008-09-24
JP2016040263A (ja) 2016-03-24
NZ569883A (en) 2011-12-22
AU2006342447B2 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
Gallo et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
Yan et al. The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
JP2016040263A (ja) 翻訳機能障害に基づく治療法
Gandhirajan et al. Small molecule inhibitors of Wnt/β-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo
Beauchamp et al. Targeting N-myristoylation for therapy of B-cell lymphomas
US10472677B2 (en) Translational dysfunction based therapeutics
Bianchi-Smiraglia et al. Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma
CA2793835C (en) Methods and compositions for cell-proliferation-related disorders
Kim et al. Plasma membrane calcium ATPase regulates bone mass by fine-tuning osteoclast differentiation and survival
Mondello et al. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
WO2020081556A2 (en) Non-canonical swi/snf complex and uses thereof
Wang et al. Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma cells to the PARP inhibitor olaparib
Schuler et al. Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis
Lehrich et al. Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
Zhang et al. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy
WO2014074805A1 (en) Selective targeting of cancer stem cells
Mahmud et al. DAXX drives de novo lipogenesis and contributes to tumorigenesis
Yan et al. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu
Jiang et al. Geranylgeranylacetone promotes human osteosarcoma cell apoptosis by inducing the degradation of PRMT1 through the E3 ubiquitin ligase CHIP
Walton et al. PRMT1 inhibition perturbs RNA metabolism and induces DNA damage in clear cell renal cell carcinoma
Zhou et al. Chaperone-mediated autophagy regulates the metastatic state of mesenchymal tumors
Ferreira et al. The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies
US12534729B2 (en) Uses of synthetic lethal partners for treatment of cancer
US20240050392A1 (en) Compositions and methods for improved treatment of platinum-based chemotherapeutic resistant tumors
Chiou et al. The RING finger E3 ligase RNF25 protects DNA replication forks independently of its canonical roles in ubiquitin signaling

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130214

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131225

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150617